Here are three quick notes:
1. Some groups opposed the 21st Century Cures Act, which loosened FDA approvals and offered NIH $8.75 billion in funding.
2. Proponents believe it will spur innovation and enhance care.
3. Opponents, however, argue the act offers an incentive for researchers to seek lawmaker endorsement of legislation that would relax drug and device approvals.
More articles on devices:
Globus Medical stock downgraded to “sell” by Goldman Sachs: 3 points
First Ray’s CortiClamp System receives FDA clearance: 4 takeaways
Stryker shares fall 0.81% — 4 notes on how the shares are faring
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
